1. Home
  2. HCM
  3. HCM News

Latest HUTCHMED (China) Limited (HCM) News on July 27, 2024

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

GlobeNewswire

23 days ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Spire Declares Dividend

PR Newswire

6 months ago

Spire Declares Dividend

Share on Social Networks: